Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women

Bone

Volumn 24, Issue 3, 1999, Pages 237-244

  Ravn, P ^a   Clemmesen, B ^a   Christiansen, C ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

Alendronate; Bone mineral density; N terminal midfragment osteocalcin; Serum C telopeptides; Urine C telopeptides; Urine N telopeptides

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; OSTEOCALCIN;

ADULT; ARTICLE; BONE MASS; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DENMARK; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN CROSS LINKING; RANDOMIZED CONTROLLED TRIAL; SPINE;

EID: 0033105942     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(98)00183-5     Document Type: Article

References (26)

1. Bjarnason N.H., Bjarnason K., Hassager C., Christiansen C. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone. 20:1997;151-155.
2. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., Bauer D.C., Genant H.K., Haskell W.L., Marcus R., Ott S.M., Torner J.C., Quandt S.A., Reiss T.F., Ensrud K.E. Randomised trial of effect of alendronate on the risk of fracture in women with existing vertebral fractures. Lancet. 348:1996;1535-1541.
3. Bonde M., Qvist P., Fledelius C., Riis B.J., Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem. 40:1994;2022-2025.
4. Chesnut C.H. III, Bell N.H., Clark G.S., Drinkwater B.L., English S.G., Johnston C.C., Notelovitz M., Rosen C., Cain D.F., Flessland K.A., Mallinak N.J.S. Hormone replacement therapy in postmenopausal women Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density . Am J Med. 102:1997;29-37.
5. Christgau, S., Rosenquist, S., Alexandersen, P., Bjarnason, N. H., Ravn, P., Fledelius, C., Herling, C., Qvist, P., and Christiansen, C. Clinical evaluation of the serum CrossLaps one step ELISA, a new assay measuring the serum concentration of bone derived degradation products of type I collagen C-telopeptides. Clin Chem 44:2290-2300; 1998.
6. Cummings S.R., Black D.M., Vogt T.M. Changes in BMD substantially underestimate the anti-fracture effect of alendronate and other antiresorptive drugs [abstract 29]. J Bone Miner Res. 11:(Suppl. 1):1996;S102.
7. Devogelaer J.P., Broll H., Correa-Rotter R., Cumming D.C., De Deuxchaisnes C.N., Geusens P., Hosking D., Jaeger P., Kaufman J.M., Leite M., Leon J., Liberman U., Menkes C.J., Meunier P.J., Reid I., Rodriguez J., Romanowicz A., Seeman E., Vermeulen A., Hirsch L.J., Lombardi A., Pleiza K., Santora A.C., Yates A.J., Yuan W. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone. 18:1996;141-150.
8. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs. 42:1991;919-944.
9. Garnero P., Gineyts E., Arbault C., Christiansen C., Delmas P.D. Different effect of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res. 10:1995;641-649.
10. Garnero P., Shih W.J., Gineyts E., Karpf D.B., Delmas P.D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 79:1994;1693-1700.
11. Garnero P., Hausherr E., Chapuy M.C., Marcelli C., Grandjean H., Muller C., Cormier C., Breart G., Meunier P.J., Delmas P.D. Markers of bone resorption predict hip fracture in elderly women The EPIDOS prospective study . J Bone Miner Res. 11:1996;1531-1538.
12. Genant H.K., Engelke K., Fuerst T., Glüer C.-C., Grampp S., Harris S.T., Jergas M., Lang T., Lu Y., Majumdar S., Mathur A., Takada M. Noninvasive assessment of bone mineral and structure State of the art . J Bone Miner Res. 11:1996;707-730.
13. Giannini S., Angelo A.D., Malvasi L., Castringnano R., Pati T., Tronca R., Liberto L., Nobile M., Crepaldi G. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone. 14:1993;137-141.
14. Harris S.T., Gertz B.J., Genant H.K., Eyre D.R., Survill T.T., Ventura J.N., Debrock J., Ricerca E., Chesnut C.H. III. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodelling in early postmenopausal women. J Clin Endocrinol Metab. 76:1993;1399-1406.
15. Heaney R.P., Yates J.A., Santora A.C. II. Bisphosphonate effects and the bone remodelling transient. J Bone Miner Res. 12:1997;1143-1151.
16. EPIC Study Group , Hosking D., Chilvers C.E.D., Christiansen C., Ravn P., Wasnich R., Ross P., McClung M., Balske A., Thompson D., Daley M., Yates A.J. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med. 338:1998;485-492.
17. The Alendronate Phase III Osteoporosis Treatment Study Group , Liberman U.A., Weiss S.R., Bröll J., Minne H.W., Quan H., Bell N.H., Rodriguez-Portales J., Downs R.W., Dequeker J., Favus M., Seeman E., Recker R.R., Capizzi T., Santora A.C. II, Lombardi A., Shah R.V., Hirsch L.J., Karpf D.B. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 333:1995;1437-1443.
18. McClung M., Clemmesen B., Daifotis A., Gilchrist N.L., Eisman J., Weinstein R.S., Fuleihan G. El-H., Reda C., Yates A.J., Ravn P. Alendronate prevents postmenopausal bone loss in women without osteoporosis A double-blind, randomized, controlled trial . Ann Intern Med. 128:1998;253-261.
19. Ravn P., Christensen J.O., Baumann M., Clemmesen B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment Prediction of bone mass changes during treatment . Bone. 22:1998;559-564.
20. Ravn P., Clemmesen B., Riis B.J., Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study . Bone. 19:1996;527-533.
21. Reginster J.Y., Lecart M.P., Deroisy R., Sarlet N., Denis D., Ethgen D., Collette J., Franchimont P. Prevention of postmenopausal bone loss by tiludronate. Lancet. 2:1989;1469-1471.
22. Reid I.R., Wattie D.J., Evans M.C., Gamble G.D., Stapleton J.P., Cornish J. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab. 79:1994;1595-1599.
23. Rosen C.J., Chesnut C.H. III, Mallinak N.J.S. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab. 82:1997;1904-1910.
24. Rosenquist C., Fledelius C., Christgau S., Pedersen B.J., Bonde M., Qvist P., Christiansen C. Serum CrossLaps™ one step ELISA First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen . Clin Chem. 44:1998;2281-2289.
25. Rosenquist C., Qvist P., Bjarnason N., Christiansen C. Measurement of a more stable structure of osteocalcin in human serum using two monoclonal antibodies in an enzyme-linked immunosorbent assay (ELISA). Clin Chem. 41:1995;1439-1445.
26. Watts N.B., Harris S.T., Genant H.K., Wasnich R.D., Miller P.D., Jackson R.D., Licata A.A., Ross P., Woodson G.C. III, Yanover M.J., Mysiew W.J., Kohse L., Rao M.B., Steiger P., Richmond B., Chesnut C.H. III. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 323:1990;73-79.